Siltuximab Biosimilar - Research Grade

Human

IL-6

>1mg/ml

Human IgG1 (E356D/M358L)-kappa

Clazakizumab Biosimilar - Research Grade (ICH5063), Olokizumab Biosimilar - Research Grade (ICH5170), Elsilimomab Biosimilar - Research Grade (ICH5516), Pacibekitug Biosimilar - Research Grade (ICH5751), Sirukumab Biosimilar - Research Grade (ICH5869), Vamikibart Biosimilar - Research Grade (ICH5966), Ziltivekimab Biosimilar - Research Grade (ICH6008)

https://www.imgt.org/mAb-DB/

ICH3002

P05231

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of siltuximab, built around the cytokine interleukin-6 (IL-6), and supplied strictly for research use only. It is not the clinical drug and is not intended for human or veterinary use. Provided as a human IgG1-kappa (with E356D/M358L substitutions) that recognizes human IL-6, it is useful as a well-characterized anti-IL-6 reagent for benchtop and preclinical research: as a positive control in binding and neutralization assays, a benchmarking standard when developing or validating IL-6-directed antibodies and biosimilars, a capture or detection tool in immunoassays, and a blocking reagent to interrogate IL-6-dependent signaling in cell-based systems. Because it neutralizes soluble IL-6 rather than the receptor, it is a clean tool for dissecting ligand-driven versus receptor-driven biology in vitro. It is offered at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay development, in-vitro standards, and scaled preclinical work. Interleukin-6 (IL-6, UniProt P05231) is a pleiotropic ~21-26 kDa four-helix-bundle cytokine and a central mediator of inflammation, acute-phase responses, and immune regulation. It is produced by macrophages, T cells, fibroblasts, and endothelial and tumor cells in response to infection and tissue injury. IL-6 signals through a two-component system: it first binds the non-signaling IL-6 receptor alpha (IL-6R, membrane-bound or soluble), and this complex then engages the shared signal-transducing subunit gp130 to trigger JAK/STAT3, RAS-MAPK, and PI3K pathways. Classic signaling (membrane IL-6R) is largely anti-inflammatory and regenerative, whereas trans-signaling via soluble IL-6R broadens responsiveness to gp130-bearing cells and drives many pro-inflammatory effects. IL-6 induces hepatic acute-phase proteins (including C-reactive protein), promotes B-cell and plasma-cell differentiation, and supports Th17 responses. Dysregulated IL-6 is implicated in autoimmune disease, cytokine-release states, and several cancers.

B-cell stimulatory factor 2, BSF-2, CTL differentiation factor, CDF, Hybridoma growth factor, Interferon beta-2, IFN-beta-2, Interleukin-6, IFNB2

Detects human IL-6

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Siltuximab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Siltuximab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Siltuximab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Siltuximab that binds human IL-6.